Molecular Medicine Research Institute (MMRI)

mmrx.org

The Molecular Medicine Research Institute (MMRI) is committed to translating scientific laboratory findings into direct patient care. Since 1995, MMRI has been exploring the molecular basis of chronic diseases and bridging the gap between science and medical practice through a unique two-part niche program.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

EVAXION BIOTECH ANNOUNCES PUBLICATION OF CLINICAL DATA OF EVX-01 HEADING INTO PHASE 2B IN COLLABORATION WITH MERCK

Evaxion Biotech | January 27, 2022

news image

Evaxion Biotech A/S a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a paper on personalized therapy with EVX-01 in patients with metastatic melanoma in the open access, peer-reviewed journal OncoImmunology. The paper, entitled, “Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvan...

Read More

Medical

WUXI ATU AND WUGEN ANNOUNCE MANUFACTURING PARTNERSHIP TO EXPEDITE THE DELIVERY OF NOVEL CELL CANCER IMMUNOTHERAPIES

Wugen | June 16, 2022

news image

WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotechnology company based in St. Louis and San Diego, today announced a partnership to produce Wugen's WU-NK-101, a novel immunotherapy that harnesses the power of memory natural killer (NK) cells to treat cancers. WuXi ATU will provide manufacturing and testing services for WU-NK-101 to enable the delivery of this innovative cell therapy produ...

Read More

MedTech, Medical

BAYLOR COLLEGE OF MEDICINE HUMAN GENOME SEQUENCING CENTER ADOPTS OLINK® EXPLORE HT PROTEOMICS PLATFORM

Globenewswire | August 09, 2023

news image

Olink Holding AB announced that the Baylor College of Medicine Human Genome Sequencing Center (BCM-HGSC) has selected the Olink Explore platform as a proteomics component of their world-class multiomics offering. Understanding the complex biological mechanisms of human diseases is essential to identifying effective new therapeutic strategies. The addition of Olink proteomic technology enables a more thorough understanding of the intricate connections between genes, proteins, and...

Read More

Cell and Gene Therapy

AKTIS ONCOLOGY ANNOUNCES ACTINIUM-225 SUPPLY AGREEMENTS WITH LEADING ISOTOPE PRODUCERS

Aktis Oncology | August 24, 2022

news image

Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced agreements with three leading medical radioisotope manufacturers NorthStar Medical Radioisotopes LLC, Niowave, Inc, and TerraPower LLC, for preclinical, clinical, and commercial supply of Actinium-225. "Given the breadth and depth of our emerging pipeline, securing robust isotope s...

Read More
news image

Industrial Impact

EVAXION BIOTECH ANNOUNCES PUBLICATION OF CLINICAL DATA OF EVX-01 HEADING INTO PHASE 2B IN COLLABORATION WITH MERCK

Evaxion Biotech | January 27, 2022

Evaxion Biotech A/S a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a paper on personalized therapy with EVX-01 in patients with metastatic melanoma in the open access, peer-reviewed journal OncoImmunology. The paper, entitled, “Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvan...

Read More
news image

Medical

WUXI ATU AND WUGEN ANNOUNCE MANUFACTURING PARTNERSHIP TO EXPEDITE THE DELIVERY OF NOVEL CELL CANCER IMMUNOTHERAPIES

Wugen | June 16, 2022

WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotechnology company based in St. Louis and San Diego, today announced a partnership to produce Wugen's WU-NK-101, a novel immunotherapy that harnesses the power of memory natural killer (NK) cells to treat cancers. WuXi ATU will provide manufacturing and testing services for WU-NK-101 to enable the delivery of this innovative cell therapy produ...

Read More
news image

MedTech, Medical

BAYLOR COLLEGE OF MEDICINE HUMAN GENOME SEQUENCING CENTER ADOPTS OLINK® EXPLORE HT PROTEOMICS PLATFORM

Globenewswire | August 09, 2023

Olink Holding AB announced that the Baylor College of Medicine Human Genome Sequencing Center (BCM-HGSC) has selected the Olink Explore platform as a proteomics component of their world-class multiomics offering. Understanding the complex biological mechanisms of human diseases is essential to identifying effective new therapeutic strategies. The addition of Olink proteomic technology enables a more thorough understanding of the intricate connections between genes, proteins, and...

Read More
news image

Cell and Gene Therapy

AKTIS ONCOLOGY ANNOUNCES ACTINIUM-225 SUPPLY AGREEMENTS WITH LEADING ISOTOPE PRODUCERS

Aktis Oncology | August 24, 2022

Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced agreements with three leading medical radioisotope manufacturers NorthStar Medical Radioisotopes LLC, Niowave, Inc, and TerraPower LLC, for preclinical, clinical, and commercial supply of Actinium-225. "Given the breadth and depth of our emerging pipeline, securing robust isotope s...

Read More